Clinical trials: Monoclonal
Rheumatoid Arthritis
Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC "BIOCAD") With Methotrexate in First Line Biological Therapy of Patients With Active Rheumatoid Arthritis
The mail goal of this study is to establish superiority in efficacy of Acellbia® applied in a dose of 600 mg (Day 1 and Day 15) in combination with methotrexate in patients with active RA seropositive previously untreated with…
- Trial name
- ALTERRA (NCT02744196)
- Testing
- Acellbia, Methotrexate
- Volunteers
- 159 people
- Sponsor
- Biocad
Autoimmune Diseases
A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis
Chemokine (C-C motif) ligand 20 (CCL20) is a protein involved in attracting immune cells including subsets of T cells (for example Th17 cells), B cells, natural killer cells and dendritic cells to inflamed tissues in conditions…
- Trial name
- NCT02671188
- Testing
- GSK3050002
- Where
- United Kingdom
- Sponsor
- GlaxoSmithKline
Smoldering Multiple Myeloma
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
The purpose of this study is to evaluate the anti-tumor activity, safety and pharmacology of two dose regimens (0.2 and 2 mg/kg)of IPH2101 in patients with Smoldering Multiple Myeloma.
- Trial name
- KIRMONO (NCT01222286)
- Testing
- IPH2101
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Innate Pharma
Hodgkin Lymphoma
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)
- Trial name
- NCT02572167
- Testing
- brentuximab vedotin, nivolumab
- Where
- 13 sites in United States
- Volunteers
- 93 people
- Sponsor
- Seagen Inc.
Non-Small-Cell Lung Cancer
A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
This trial is designed to evaluate the efficacy, safety and immunogenicity of neoadjuvant treatment with monoclonal antibody SHR-1316 or placebo in combination with platinum doublet chemotherapy in participants with resectable…
- Trial name
- NCT04316364
- Testing
- SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin, SHR-1316、Chemotherapeutic
- Where
- 7 sites in China
- Volunteers
- 537 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Moderate to Severe Asthma
A Study of CM310 in Subjects With Moderate to Severe Asthma
This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe…
- Trial name
- NCT05761028
- Testing
- CM310
- Where
- China
- Volunteers
- 600 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Kidney Transplant Rejection
Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation
This study will evaluate the efficacy and safety of tegoprubart compared with tacrolimus in adult participants undergoing first kidney transplantation.
- Trial name
- LEGACY (NCT07835581)
- Testing
- Tegoprubart, Tacrolimus
- Volunteers
- 620 people
- Sponsor
- Eledon Pharmaceuticals
Multiple Myeloma
An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of siltuximab in participants with relapsed (the return of a disease or the signs and symptoms of a disease after a period of improvement.) or refractory (cancer…
- Trial name
- NCT00402181
- Testing
- Siltuximab, Dexamethasone
- Where
- 13 sites in United States, Netherlands
- Volunteers
- 53 people
- Sponsor
- Centocor, Inc.
Multiple Sclerosis
Safety Study of GNbAC1 in Multiple Sclerosis Patients
The purpose of this study is to assess the safety and tolerability of single ascending doses, as well as of repeated administrations of GNbAC1 in MS patients.
- Trial name
- NCT01639300
- Testing
- GNbAC1
- Where
- 2 sites in Switzerland
- Volunteers
- 10 people
- Sponsor
- GeNeuro Innovation SAS
Cancer
Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors
JTX-8064-101 is a Phase 1/2, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose (RP2D) of JTX-8064 alone and in combination with a PD-1 inhibitor…
- Trial name
- NCT04669899
- Testing
- JTX-8064, pimivalimab
- Where
- 45 sites in United States
- Volunteers
- 190 people
- Sponsor
- Jounce Therapeutics, Inc.
Metastatic Malignant Neoplasm
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2) that may potentiate an anti-tumor immune response.
- Trial name
- NCT06240728
- Testing
- NPX887
- Where
- 8 sites in United States, South Korea
- Volunteers
- 144 people
- Sponsor
- NextPoint Therapeutics, Inc.
Non Small Cell Lung Cancer
First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin
The research study is testing the investigational drug necitumumab in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy…
- Trial name
- INSPIRE (NCT00982111)
- Testing
- Pemetrexed, Cisplatin, Necitumumab
- Where
- 101 sites in United States, Australia and 18 more
- Volunteers
- 633 people
- Sponsor
- Eli Lilly and Company
Triple Negative Breast Cancer, Pancreatic Carcinoma
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this study of MCS110 with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with…
- Conditions
- Triple Negative Breast Cancer, Pancreatic Carcinoma, Melanoma, Endometrial Carcinoma
- Trial name
- NCT02807844
- Testing
- MCS110, PDR001
- Where
- 20 sites in United States, Belgium and 9 more
- Volunteers
- 141 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer
The aim of this Study Protocol is to provide a basis for the clinical development of 131I-F16SIP as an anti-cancer therapeutic agent.
- Trial name
- NCT01240720
- Testing
- 131I-F16SIP Radioimmunotherapy (RIT)
- Where
- 6 sites in Italy
- Volunteers
- 65 people
- Sponsor
- Philogen S.p.A.
Cervical Cancer
AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
This study tested how well and how safely the drug tislelizumab, given either alone or with another drug called ociperlimab (BGB-A1217), worked in people with cervical cancer that had come back or spread after previous…
- Trial name
- NCT04693234
- Testing
- Tislelizumab, Ociperlimab
- Where
- 68 sites in Bulgaria, China and 6 more
- Volunteers
- 178 people
- Sponsor
- BeiGene
Chronic Scalp Psoriasis
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
This study will assess the efficacy and safety of secukinumab compared to placebo in adult patients who have moderate to severe scalp psoriasis that is poorly controlled by current psoriasis treatments.
- Trial name
- SCALP (NCT02267135)
- Testing
- Secukinumab 300 mg
- Where
- 17 sites in United States
- Volunteers
- 102 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
The study will assess the long-term safety and tolerability of AIN457 in patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT01433250
- Testing
- AIN457
- Where
- 14 sites in Czechia, Russia and 1 more
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma
Primary Objective: To evaluate the pharmacokinetics (PK) of isatuximab. Secondary Objectives: To evaluate the safety and tolerability of isatuximab. To assess the preliminary antitumor effect of isatuximab.
- Trial name
- NCT03733717
- Testing
- Isatuximab SAR650984
- Where
- 3 sites in China
- Volunteers
- 25 people
- Sponsor
- Sanofi
Chronic Lymphocytic Leukemia (CLL)
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
The overall purpose of the study was to determine if MEDI-551, when used in combination with salvage chemotherapy (bendamustine) in participants with relapsed or refractory CLL who are not eligible for Autologous Stem Cell…
- Trial name
- NCT01466153
- Testing
- Rituximab, Bendamustine, MEDI-551
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 183 people
- Sponsor
- MedImmune LLC
Cutaneous T-Cell Lymphoma
Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
The primary objective of this first in human study is to assess the safety and tolerability of increasing intravenous (IV) doses of single agent IPH4102 administered to patients with relapsed/refractory CTCL to characterize the…
- Trial name
- NCT02593045
- Testing
- IPH4102
- Where
- 5 sites in United States, France and 2 more
- Volunteers
- 44 people
- Sponsor
- Innate Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.